Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2023
Same author

Common Neurologic Features of Lyme Disease That May Present to a Rheumatologist.

Pathogens (Basel, Switzerland)·2023
Same author

Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.

Multiple sclerosis and related disorders·2015
Same author

Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.

BMJ open·2014
Same author

Pregnancy and multiple sclerosis.

Neurologic clinics·2012
Same author

Invited article: The ABPN maintenance of certification program for neurologists: past, present, and future.

Neurology·2008
Same journal

Hepatitis B Infection-Associated Aortoarteritis.

Annals of Indian Academy of Neurology·2026
Same journal

Correspondence- Muscle Magnetic Resonance Imaging Phenotyping and Pattern Recognition in Genetically Confirmed Myopathies: A Large-Cohort Study from the Indian Subcontinent.

Annals of Indian Academy of Neurology·2026
Same journal

STAC3-Related Congenital Myopathy (CMYP13) in an Adult Indian Patient: Expanding the Geographic Spectrum to India.

Annals of Indian Academy of Neurology·2026
Same journal

A Prospective Study on Autonomic Functions in Idiopathic Inflammatory Myopathies: The AFIIM Study.

Annals of Indian Academy of Neurology·2026
Same journal

Magnetic Resonance Imaging Findings During Encephalopathic Crisis in Glutaric Aciduria Type 1: Expanding the Radiologic Phenotype.

Annals of Indian Academy of Neurology·2026
Same journal

Thyroid Function and Cognitive Health in Older Adults: Insights from the LASI-DAD Study.

Annals of Indian Academy of Neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Disease-modifying agents in multiple sclerosis.

P K Coyle1

  • 1Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York, USA.

Annals of Indian Academy of Neurology
|February 26, 2010
PubMed
Summary
This summary is machine-generated.

Six disease-modifying therapies (DMTs) benefit multiple sclerosis (MS) patients, with choices depending on drug, disease, and patient factors. This review covers current and alternative MS treatments.

Keywords:
Disease-modifying agentsglatiramer acetateinterferon betamultiple sclerosis therapynatalizumab

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: Jun 15, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple Sclerosis (MS) management has evolved with approved disease-modifying therapies (DMTs).
  • Efficacy data for some available MS treatments remain limited.
  • Current DMTs are primarily indicated for relapsing forms of MS.

Purpose of the Study:

  • To review currently utilized DMTs for multiple sclerosis.
  • To discuss alternative agents for MS treatment.
  • To provide insights into selecting appropriate MS therapies.

Main Methods:

  • Review of phase III clinical trial data for established MS therapies.
  • Analysis of factors influencing treatment selection.
  • Discussion of alternative agents with limited efficacy data.

Main Results:

  • Six DMTs have demonstrated efficacy in rigorous clinical trials for MS.
  • Treatment choice is multifactorial, involving drug, disease, and patient considerations.
  • Alternative agents exist but lack definitive efficacy data.

Conclusions:

  • Disease-modifying therapy is crucial for managing relapsing forms of MS.
  • Personalized treatment selection optimizes outcomes in multiple sclerosis care.
  • Further research is needed for alternative MS agents.